Abstract
Cardiac amyloidosis is a heterogeneous group of diseases based on deposits of protein myofibrils in the cardiac muscle and surrounding tissues. There are several types of these diseases according to the types of deposits, and in the case of heart disease we most frequently encounter impairment in depositing light chains or transthyretin.
Early diagnosis is very important because, these days, specific treatment can affect the course of the disease and its success depends on the progression of the disease at the time of commencing treatment. Over the last few years, there have been relatively fundamental changes in diagnostics (bone scintigraphy) and treatment, especially of transthyretin amyloidosis (tafamidis, etc.).
This article summarizes current findings regarding the diagnosis and treatment options of cardiac amyloidosis.